{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:51:42Z","timestamp":1761562302754,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.carrev.2018.04.012","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T02:38:23Z","timestamp":1523932703000},"page":"452-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of mineralocorticoid receptor antagonists in patients with acute myocardial infarction: Is the evidence reflective of modern clinical practice?"],"prefix":"10.1016","volume":"19","author":[{"given":"Jonathan","family":"Hinton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Myat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Curzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.carrev.2018.04.012_bb0005","first-page":"e29","article-title":"Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.carrev.2018.04.012_bb0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"year":"2010","series-title":"Oxford textbook of interventional cardiology","author":"Redwood","key":"10.1016\/j.carrev.2018.04.012_bb0015"},{"key":"10.1016\/j.carrev.2018.04.012_bb0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IBPC.S13783","article-title":"Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine","volume":"6","author":"Funder","year":"2013","journal-title":"Integr Blood Press Control"},{"key":"10.1016\/j.carrev.2018.04.012_bb0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.carrev.2018.04.012_bb0030","first-page":"e362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.carrev.2018.04.012_bb0035","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.04.012_bb0040","first-page":"6","article-title":"Mineralocorticoid receptor antagonist in heart failure: past, present and future perspectives","volume":"3","author":"Vizzardi","year":"2014","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.carrev.2018.04.012_bb0045","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/0002-9149(93)90238-8","article-title":"Aldosterone and antialdosterone therapy in congestive heart failure","volume":"71","author":"Weber","year":"1993","journal-title":"Am J Cardiol"},{"year":"2005","series-title":"Medical pharmacology and theraputics","author":"Waller","key":"10.1016\/j.carrev.2018.04.012_bb0050"},{"issue":"3","key":"10.1016\/j.carrev.2018.04.012_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4331\/wjbc.v6.i3.209","article-title":"Inflammation, oxidative stress and renin angiotensin system in atherosclerosis","volume":"6","author":"Husain","year":"2015","journal-title":"World J Biol Chem"},{"issue":"Supplement A","key":"10.1016\/j.carrev.2018.04.012_bb0060","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/S1520-765X(03)90057-5","article-title":"Oxidative stress, the renin-angiotensin system, and atherosclerosis","volume":"5","author":"Landmesser","year":"2003","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.carrev.2018.04.012_bb0065","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/CIRCRESAHA.116.309326","article-title":"Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis","volume":"120","author":"F\u00f6rstermann","year":"2017","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.carrev.2018.04.012_bb0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.carrev.2018.04.012_bb0075","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.carrev.2018.04.012_bb0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ejhf.88","article-title":"Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial","volume":"16","author":"Iqbal","year":"2014","journal-title":"Eur J Heart Fail"},{"author":"Myocardial Ischaemia National Audit Project: National Institute for Cardiovascular Outcomes Research","key":"10.1016\/j.carrev.2018.04.012_bb0085"},{"issue":"1 Pt B","key":"10.1016\/j.carrev.2018.04.012_bb0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcin.2014.07.017","article-title":"Increasing percutaneous coronary interventions for ST-segment elevation myocardial infarction in the United States: progress and opportunity","volume":"8","author":"Shah","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.carrev.2018.04.012_bb0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jcin.2017.12.016","volume":"11","author":"Malta Hansen","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"20","key":"10.1016\/j.carrev.2018.04.012_bb0100","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1161\/CIRCULATIONAHA.117.030798","article-title":"Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20\u202fyears in the FAST-MI program (French registry of acute ST-elevation or non-ST-elevation myocardial infarction) 1995 to 2015","volume":"136","author":"Puymirat","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.04.012_bb0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2017.09.010","article-title":"Mineralocorticoid receptor antagonists in patients with acute myocardial infarction \u2014 a systematic review and meta-analysis of randomized trials","volume":"195","author":"Bossard","year":"2018","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.carrev.2018.04.012_bb0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.acvd.2014.01.010","article-title":"Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: a post hoc substudy of the EPHESUS trial","volume":"107","author":"Carillo","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.carrev.2018.04.012_bb0115","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jacc.2003.08.055","article-title":"Short- and long-term recovery of left ventricular function predicted at the time of primary percutaneous coronary intervention in anterior myocardial infarction","volume":"43","author":"Bax","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.carrev.2018.04.012_bb0120","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/eurheartj\/ehi131","article-title":"Recovery of left ventricular function after primary angioplasty for acute myocardial infarction","volume":"26","author":"Baks","year":"2005","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.carrev.2018.04.012_bb0125","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.carrev.2018.04.012_bb0130","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.carrev.2018.04.012_bb0135","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ahj.2008.12.013","volume":"157","author":"Beygui","year":"2009","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.carrev.2018.04.012_bb0140","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.amjcard.2010.04.019","article-title":"Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates","volume":"106","author":"Beygui","year":"2010","journal-title":"Am J Cardiol"},{"issue":"20","key":"10.1016\/j.carrev.2018.04.012_bb0145","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/eurheartj\/ehn383","article-title":"Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction","volume":"29","author":"Palmer","year":"2008","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.carrev.2018.04.012_bb0150","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/01.CIR.0000138973.55605.38","article-title":"Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction","volume":"110","author":"Perrier","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.carrev.2018.04.012_bb0155","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","article-title":"Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response","volume":"51","author":"Fraccarollo","year":"2008","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.carrev.2018.04.012_bb0160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2011.11.076","article-title":"Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia","volume":"167","author":"Beygui","year":"2013","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.carrev.2018.04.012_bb0165","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCHEARTFAILURE.112.968180","article-title":"Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION registry","volume":"5","author":"Shah","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"16","key":"10.1016\/j.carrev.2018.04.012_bb0175","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"10.1016\/j.carrev.2018.04.012_bb0180","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.04.012_bb0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00392-017-1157-3","article-title":"Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study","volume":"107","author":"Ferreira","year":"2018","journal-title":"Clin Res Cardiol"},{"issue":"23","key":"10.1016\/j.carrev.2018.04.012_bb0190","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/eurheartj\/eht090","article-title":"Myocardial reperfusion injury: looking beyond primary PCI","volume":"34","author":"Fr\u00f6hlich","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.04.012_bb0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2016.04.150","article-title":"Eplerenone does not limit ischemia-reperfusion injury in human myocardial tissue","volume":"216","author":"van den Berg","year":"2016","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.carrev.2018.04.012_bb0205","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/clc.22401","article-title":"Mineralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-elevation myocardial infarction (the MINIMISE STEMI trial): rationale and study design","volume":"38","author":"Bulluck","year":"2015","journal-title":"Clin Cardiol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918301428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918301428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:13:50Z","timestamp":1761560030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838918301428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1553838918301428"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2018.04.012","relation":{},"ISSN":["1553-8389"],"issn-type":[{"type":"print","value":"1553-8389"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of mineralocorticoid receptor antagonists in patients with acute myocardial infarction: Is the evidence reflective of modern clinical practice?","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2018.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}